Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets
about
sameAs
Cannabinoids in health and diseaseThe endocannabinoid system as an emerging target of pharmacotherapyEndocannabinoid system: emerging role from neurodevelopment to neurodegeneration.Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liabilityEndocannabinoids in synaptic plasticity and neuroprotection.The endocannabinoid system as a target for the treatment of neurodegenerative disease.The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ an[¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's diseaseUpregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption.The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.Endocannabinoid signaling in midbrain dopamine neurons: more than physiology?Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats.The therapeutic potential of cannabinoids for movement disorders.Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's diseasePromising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionNew insights on endocannabinoid transmission in psychomotor disorders.Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.Cannabinoids and value-based decision making: implications for neurodegenerative disorders.Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.The endocannabinoid system as a target for the treatment of motor dysfunction.The endocannabinoid system in neuropathological states.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Endocannabinoid modulation of dopaminergic motor circuits.Dyskinesias in Parkinson's disease: views from positron emission tomography studies.The endocannabinoid system: a putative role in neurodegenerative diseases.Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Endocannabinoid system in neurodegenerative disorders.Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats.Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonismCannabinoids in Parkinson's DiseaseNeurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance.The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases.Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine.Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function.
P2860
Q24633884-937666E8-C900-4DDD-AD7A-51936F79308AQ24648473-F711763B-65D5-487C-9527-CD8BE3EA28BDQ30391852-2AAF3129-680F-4696-9DED-259388D10206Q30493991-3621B73C-9D92-4238-89DA-F7819D39B654Q33751118-3B879619-527E-439B-9A7D-B6E9603BC0D8Q34084682-554A25B2-8683-4A9A-B57E-D5D8CCBAF04CQ34098196-A3B79FFF-E170-4FCE-8EBC-069D321523D6Q34267133-1FC6EB30-AF32-428C-B285-E440E5459265Q34269852-D85121B6-7CD5-447F-9655-505F25133B7AQ34419703-8EA81421-93B4-4070-8782-F829BE7CD9E0Q34626755-29E7025E-75A7-4F51-A379-38A13C5062D0Q34680801-9003AA0B-3426-4C73-AA59-C0512E392E64Q34967151-709D9677-8DF4-4514-9BCC-D4BDC881FB75Q35014951-34EB9CB7-3ED6-46B1-AC99-C8DBA98F8C7AQ35171113-173327A5-42B5-4606-893A-72A7DDFD4847Q35193305-C76967B1-95FA-4952-AA0D-5443F148737DQ35499568-AA19312D-6346-4241-B5FE-66A20D43C77EQ36074595-0CD2CEA2-1DCE-4F8C-ADC4-3F972C07D075Q36157657-F9182590-A0A5-49B1-A153-F2EB9871BB8EQ36341688-318711F2-A0E4-4BB9-B0EC-14E9475E7045Q36393644-33089887-E0FD-41B5-BBE5-F233647EA682Q36861976-5A6D573E-7DC1-4906-B195-3E1B98FF999EQ37394164-A9B7B00C-CEE9-49B7-AD78-62CA756DF5E5Q37444824-161B5A7C-6DE1-4437-9ED7-E188C954DA56Q37512670-3468606F-B934-4824-BC4B-17611DE810A2Q38018946-13024795-EB65-490E-975C-25E750007A1DQ38182651-ED49C751-A7E5-4BCA-8DB3-7142E0E7BA62Q38223774-959710A5-4EE4-4BFA-A72F-84CF15C92BFBQ38522769-E2BD5340-7F4C-44C8-A495-F3805633C05CQ38563981-F0BAF1EC-E14A-4AAF-A17A-ACC04E9B17C1Q39368845-FA3B5C83-CEB6-4797-937C-FF556B4ACCA0Q41809772-F4ACCF49-7FA3-4C08-BE54-A694E3EB6190Q42095959-8FC3A480-1862-442C-8F68-D60D2B5EA8A0Q42258332-0250867A-FC2A-4469-8AD9-AC97E120215AQ42380034-E2F63FEF-0B33-404B-AC27-FA3C3C1A30F8Q42495608-1A4253E9-204B-417E-9ADF-C2AD495B3D92Q42500348-BE1F4780-CB1B-42E3-800F-784A8D17B0AFQ42646021-EA63818A-8602-45D7-BDD6-3B713B9FA37DQ43064653-29FDAD02-E00F-4F7D-94FE-6DDE8216E2D2Q44793025-06A16280-9AC8-499A-A906-8C6554BD863E
P2860
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@ast
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@en
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@nl
type
label
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@ast
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@en
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@nl
prefLabel
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@ast
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@en
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@nl
P2093
P2860
P921
P1476
Increased cannabinoid CB1 rece ...... and of MPTP-treated marmosets
@en
P2093
J J Fernández-Ruiz
P2860
P304
P356
10.1046/J.0953-816X.2001.01812.X
P407
P577
2001-12-01T00:00:00Z